25 February 2020

The cervical screening program was established to identify increased risk of cervical cancer in women aged between 30 and 60 years. Cervical cancer is caused by a long-term virus infection: the human papillomavirus (HPV). Early detection of HPV can prevent cervical cancer. The Biobank BVO contains left-over cytological material from the cervical screening program. The ambition of the BVO Biobank is to make this residual material available for scientific research to optimize the current cervical cancer screening program. Moreover, it aims to create a more personalized intervention by promoting better understanding of the oncogenic progression and transformation of high-risk HPV (hrHPV) infected cells and the identification/testing of biomarkers or biomarker profiles.
 
  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud biobank

Related news items


Radboud Biobank Office Relocation

30 January 2025

We would like to inform you about the upcoming relocation of the Radboud Biobank office.

read more

Request for DNA samples from stored whole blood and/or saliva

30 January 2025

There are biobank collections that collected whole blood and saliva before joining the Radboud Biobank to isolate DNA from them later.

read more

Great news!

30 January 2025

We have good news for both new and existing collections and projects interested in isolating PBMCs (Peripheral Blood Mononuclear Cells)!

read more

BBMRI-ERIC launches 10-Year Roadmap: Biobanking for a Healthier World

30 January 2025

BBMRI-ERIC, the European research infrastructure for biobanking and biomolecular resources, has launched its visionary 10-Year Roadmap (2025-2035).

read more

New business model for the Radboud Biobank

24 November 2024

The Radboudumc Board of Directors decided, after receiving advice from the UMC council, to change the Radboud Biobank business model.  

read more